Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

A2 Biotherapeutics is the lead sponsor of 5 current clinical trials in our USA register. 3 are recruiting patients now. The most common phase is Phase 1/2. The most-studied condition is Solid Tumor, Adult.

ClinicalTrials.gov trials by status

Recruiting360%
Active, closed120%
By invitation120%

Trials by phase

Phase 1/2360%
Observational240%

Clinical trials sponsored by A2 Biotherapeutics

5 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression NCT06682793 · ClinicalTrials.gov ↗ · Solid Tumor, Adult, Colorectal Cancer, Non-Small Cell Lung	Phase 1/2	Recruiting	2025-05	USA
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression NCT06051695 · ClinicalTrials.gov ↗ · Solid Tumor, Adult, Colorectal Cancer, NSCLC	Phase 1/2	Recruiting	2024-04	USA
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing NCT04981119 · ClinicalTrials.gov ↗ · Solid Tumor, Adult, Colorectal Cancer, Non Small Cell Lung Cancer	Observational	Recruiting	2021-10	USA
A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products NCT06885424 · ClinicalTrials.gov ↗ · Solid Tumor Cancer, Solid Tumor, Unspecified, Adult, Colorectal Carcinoma	Observational	By invitation	2025-07	USA
A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression NCT05736731 · ClinicalTrials.gov ↗ · Solid Tumor, Adult, Solid Tumor, Pancreatic Cancer	Phase 1/2	Active, closed	2023-04	USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Conditions in A2 Biotherapeutics trials

13 conditions

Solid Tumor, Adult4 Colorectal Cancer3 Non Small Cell Lung Cancer2 Pancreatic Cancer2Non-Small Cell Lung1NSCLC (Non-small Cell Lung Cancer)1 NSCLC1 Solid Tumor Cancer1Solid Tumor, Unspecified, Adult1Colorectal Carcinoma1Colorectal Carcinoma (CRC)1Solid Tumor1 Pancreatic Neoplasms1

By trial register

Register	Trials	Recruiting
Clinical trials in USA	5	3

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Solid Tumor, Adult

Sponsor	Trials
Second Affiliated Hospital of Guangzhou Medical University	8
Ion Beam Applications	3
Hutchmed	2
iOnctura	1
Corbus Pharmaceuticals	1
Shenzhen Ionova Life Sciences	1
Rise Therapeutics	1
EpicentRx	1
GV20 Therapeutics	1
Suzhou Abogen Biosciences	1

Sponsors with the most current trials registered for this condition.

Questions about A2 Biotherapeutics trials

How many clinical trials does A2 Biotherapeutics sponsor?

A2 Biotherapeutics is the lead sponsor of 5 current trials on ClinicalTrials.gov in our USA register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are A2 Biotherapeutics trials recruiting?

Yes. 3 of its 5 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

A2 Biotherapeutics clinical trials